Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Lifitegrast · Xiidra, SAR-1118

Small molecule · Antagonist of LFA-1 (ITGAL) · developed by Bausch And Lomb

Approved FDA, Jul 2016

BHC Developer

4 Registered trials

What is Lifitegrast?

Lifitegrast is a small-molecule LFA-1 antagonist that binds to the integrin LFA-1 on leukocytes and blocks its interaction with ICAM-1, inhibiting T-cell adhesion and migration to ocular tissues.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Xiidra, SAR-1118, SHP-606
Drug type: Small molecule
Targets: LFA-1 (ITGAL), ICAM-1 (binding partner it blocks)
Mechanism: Antagonist of LFA-1 (ITGAL)
Pathways: T-cell activation, leukocyte adhesion
Therapy area: Ophthalmology
Developer: Bausch And Lomb Inc (BHC)
FDA status: Approved as Xiidra (July 11, 2016), NDA208073 · FDA label
UNII: 038E5L962W

✅ FDA-approved uses

Dry eye disease

From the indications section of the FDA label (version of Aug 18, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07490535	Phase 4	Ocular Surface Disease	Not yet recruiting	BHC
NCT07111013	Phase 3	Dry Eye Disease	Withdrawn	BHC
NCT07128628	Phase 2	Dry Eye Disease	Completed	BHC
NCT04354545	N/A	Glaucoma	Recruiting	BHC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Dry Eye Syndrome (DES)GlaucomaOcular Surface DiseaseDry Eye Disease

More from Bausch And Lomb

Adapalene / Benzoyl Peroxide / Clindamycin FDA approved Brodalumab FDA approved Bupropion FDA approved Halobetasol Propionate And Tazarotene FDA approved IDP-118 FDA approved IDP-126 FDA approved Perfluorohexyloctane FDA approved Plecanatide FDA approved Rifaximin FDA approved Timolol FDA approved BL1107 Phase 2 BL1332 Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the BHC page.

Follow BHC, the company behind Lifitegrast

See BHC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BHC catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z